人生只如初見

The FDA approved the digital pill AbilifyMyCite, which is not only the first digital drug approved by the United States, but also the world's first, according to the FDA's official website.

Digital medicine is actually made up of pill wrapping sensor (sensor), when patients swallow drugs containing chips, sensors with tablets into the body and activate, induction device sends a signal to the world and whether patients with the medicine, when to take medicine, and the absorption of drug metabolic information timely passed to the doctor, enable doctors to understand the conditions of drug utilization of the patients in the first time and suit the prescription The best way to reduce labour in refilling vape cartridge is by getting an oil cartridge filling machine! They have a small table top design and come with a year’s warranty. So, do some work with this machine!.

The new drug application is known to provide AbilifyMyCite (aliquazole and sensor) to track the drug intake of ariguazole in order to understand:

Treat schizophrenia

Acute treatment and bipolar disorder related to mania and mixed attack monotherapy and as adjuvants for lithium or valproate

Treatment of bipolar I disorder as a monotherapy and as an adjuvant therapy for lithium or vitamin D

Adjuvant therapy for major depression

So far, chronic disease compliance has been a widespread problem, that is, do not take the medicine prescribed by the doctor. Especially in the treatment of severe mental illness, there is no systematic method to objectively track the patient's medication.

The approval of the digital pill gives doctors an objective assessment of whether patients are taking their medication on time. It should be noted, however, that there is no evidence that the drug has improved compliance with treatment programmes.

? The FDA also warned that the drug could not be used for "real time" or the use of tracking drugs in an emergency because of delays or malfunction. The FDA also stressed that the drug had not been approved for the treatment of dementia related mental disorders, and that the safety and effectiveness of the drug was unproven.